NCT05959889View on ClinicalTrials.gov

Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 1, 2024

Conditions
Breast CancerDoxorubicin Induced Cardiotoxicity
Interventions
OTHER

Placebo

Patients will receive placebo tablets for 4 cycles of AC.

DRUG

Montelukast

Patients will receive motelukast 10 mg for 4 cycles of AC.

Trial Locations (1)

31527

Damanhour Oncology Center, Damanhūr

All Listed Sponsors
lead

Damanhour University

OTHER